An experimental Covid-19 vaccine developed by Britain's GlaxoSmithKline and Sanofi has been found to show an 'insufficient immune response' in clinical trial results, in a blow to efforts to fight the pandemic.
The two companies said they planned to launch another study next year, hoping to come up with a more effective vaccine by the end of 2021.
The results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults.
Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur, said: “We care greatly about public health which is why we are disappointed by the delay announced today, but all our decisions are and will always be driven by
Read more on mirror.co.uk